Association of Coenzyme Q10 with Premature Ovarian Insufficiency

Reprod Sci. 2023 May;30(5):1548-1554. doi: 10.1007/s43032-022-01136-1. Epub 2022 Dec 5.

Abstract

The aim of the study was to analyze the relationship between levels of coenzyme Q10 (CoQ10) and the risk of premature ovarian insufficiency (POI). In this cross-sectional case-control study, 32 women with POI and 58 women with normal menstrual cycles were recruited. The serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), CoQ10 and total cholesterol were measured. The association of CoQ10 with POI was assessed using binary logistic regression analysis. The CoQ10/total cholesterol ratio was significantly lower in the women with POI than in the women with normal menstrual cycles (120.94 ± 25.35 nmol/mmol vs 138.97 ± 39.19 nmol/mmol, P = 0.021). The serum CoQ10/total cholesterol ratio was inversely associated with POI (the unadjusted odds ratio (OR) = 0.984, 95% CI: 0.970-0.998, P = 0.027). The same trend was found after adjusting for confounding factors (such as age, body mass index, annual household income and education) (OR = 0.976, 95% CI: 0.956-0.996, P = 0.020). The serum CoQ10/total cholesterol ratio was inversely associated with POI, indicating that antioxidant deficiency may be a risk associated with the development of POI. CoQ10 may be a protective factor for ovarian tissue.

Keywords: Coenzyme Q10; Oxidative stress; Premature ovarian insufficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Mullerian Hormone
  • Case-Control Studies
  • Cholesterol
  • Cross-Sectional Studies
  • Female
  • Follicle Stimulating Hormone
  • Humans
  • Menopause, Premature*
  • Primary Ovarian Insufficiency*

Substances

  • coenzyme Q10
  • Follicle Stimulating Hormone
  • Cholesterol
  • Anti-Mullerian Hormone